Advantages of laserphyrin compared with photofrin in photodynamic therapy for bile duct carcinoma

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 18, Issue 4, 2011, Pages 592-600

  Nonaka, Takashi ^a   Nanashima, Atsushi ^a   Nonaka, Mihoko ^a   Uehara, Masataka ^a   Isomoto, Hajime ^b   Nonaka, Yoshikazu ^a   Nagayasu, Takeshi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

Apoptosis; Bile duct carcinoma; Laserphyrin; Local ablation; Photodynamic therapy

Indexed keywords

CYCLINE; CYTOSTATIC AGENT; PHOTOFRIN; TALAPORFIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ASSESSMENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENCY; ENERGY TRANSFER; HUMAN; HUMAN CELL; LABELING INDEX; LIGHT EXPOSURE; LONG TERM EXPOSURE; MALE; MOUSE; NICK END LABELING; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; BILE DUCT NEOPLASMS; CARCINOMA; DIHEMATOPORPHYRIN ETHER; IN SITU NICK-END LABELING; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; TREATMENT OUTCOME;

EID: 80052672433     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1007/s00534-011-0377-6     Document Type: Article

References (41)

1. McCaughan JS Jr, Mertens BF, Cho C, Barabash RD, Payton HW. Photodynamic therapy to treat tumors of the extrahepatic biliary ducts. A case report. Arch Surg. 1991;126:111-3.
2. Witzigmann H, Berr F, Ringel U, Caca K, Uhlmann D, Schoppmeyer K, et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg. 2006;244:230-9. (Pubitemid 44305537)
3. Ortner MA, Liebetruth J, Schreiber S, Hanft M, Wruck U, Fusco V, et al. Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology. 1998;114:536-42.
4. Berr F, Wiedmann M, Tannapfel A, Halm U, Kohlhaw KR, Schmidt F, et al. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology. 2000;31:291-8. (Pubitemid 30078590)
5. Rumalla A, Baron TH, Wang KK, Gores GJ, Stadheim LM, de Groen PC. Endoscopic application of photodynamic therapy for cholangiocarcinoma. Gastrointest Endosc. 2001;53:500-4. (Pubitemid 33586760)
6. Ortner ME, Caca K, Berr F, Liebetruth J, Mansmann U, Huster D, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology. 2003;125:1355-63. (Pubitemid 37409755)
7. Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann JF. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol. 2005;100:2426-30.
8. Zoepf T. Photodynamic therapy of cholangiocarcinoma. HPB (Oxford). 2008;10:161-3. (Pubitemid 352016239)
9. Nanashima A, Yamaguchi H, Shibasaki S, Ide N, Sawai T, Tsuji T, et al. Adjuvant photodynamic therapy for bile duct carcinoma after surgery: a preliminary study. J Gastroenterol. 2004;39: 1095-101. (Pubitemid 39618794)
10. Gao Fei, Bai Yu, Shu-Ren Ma, Liu Feng, Zhao-Shen Li. Systematic review: photodynamic therapy for unresectable cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2010;17:125-31.
11. Gomer CJ, Rucker N, Ferrario A, Wong S. Properties and applications of photodynamic therapy. Radiat Res. 1989;120: 1-18. (Pubitemid 19245551)
12. Roberts WG, Shiau FY, Nelson JS, Smith KM, Berns MW. In vitro characterization of monoaspartyl chlorin e6 and diaspartyl chlorin e6 for photodynamic therapy. J Natl Cancer Inst. 1988;80:330-6.
13. Ferrario A, Kessel D, Gomer CJ. Metabolic properties and photosensitizing responsiveness of mono-L-aspartyl chlorin e6 in a mouse tumor model. Cancer Res. 1992;52:2890-3.
14. Roberts WG, Smith KM, McCullough JL, Berns MW. Skin photosensitivity and photodestruction of several potential photodynamic sensitizers. Photochem Photobiol. 1989;49:431-8.
15. Kasuya K, Shimazu M, Suzuki M, Kuroiwa Y, Usuda J, Itoi T, et al. Novel photodynamic therapy against biliary tract carcinoma using mono-L-aspartyl chlorine e6: basic evaluation for its feasibility and efficacy. J Hepatobiliary Pancreat Sci. 2010;17: 313-21.
16. Kato H, Furukawa K, Sato M, Okunaka T, Kusunoki Y, Kawahara M, et al. Phase II clinical study of photodynamic therapy using mono-L-aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung. Lung Cancer. 2003;42:103-11. (Pubitemid 37153142)
17. Nonaka T, Nanashima A, Nonaka M, Uehara M, Isomoto H, Asahina I, et al. Analysis of apoptotic effects induced by photodynamic therapy in a human biliary cancer cell line. Anticancer Res. 2010;30:2113-8.
18. Uehara M, Sano K, Wang ZL. Enhancement of the photodynamic antitumor effect by streptococcal preparation OK-432 in the mouse carcinoma. Cancer Immunol Immunother. 2000;49:401-9.
19. Wu LC, D'Amelio F, Fox RA, Polyakov I, Daunton NG. Light microscopic image analysis system to quantify immunoreactive terminal area apposed to nerve cells. J Neurosci Methods. 1997;74:89-96. (Pubitemid 27250253)
20. Oleinick NL, Morris RL, Belichenko I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci. 2002;1:1-21. (Pubitemid 37069701)
21. Luo Y, Chang CK, Kessel D. Rapid initiation of apoptosis by photodynamic therapy. Photochem Photobiol. 1996;63:528-34. (Pubitemid 126468331)
22. Gomer CJ, Ferrario A, Luna M, Rucker N, Wong S. Photodynamic therapy: combined modality approaches targeting the tumor microenvironment. Lasers Surg Med. 2006;38:516-21.
23. Dougherty TJ. An update on photodynamic therapy applications. J Clin Laser Med Surg. 2002;20:3-7. (Pubitemid 34174326)
24. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, et al. Photodynamic therapy. J Natl Cancer Inst. 1998;90:889-905. (Pubitemid 28304157)
25. Ahmad N, Mukhtar H. Mechanism of photodynamic therapyinduced cell death. Methods Enzymol. 2000;319:342-58.
26. Usuda J, Okunaka T, Furukawa K, Tsuchida T, Kuroiwa Y, Ohe Y, et al. Increased cytotoxic effects of photodynamic therapy in IL-6 gene transfected cells via enhanced apoptosis. Int J Cancer. 2001;93:475-80. (Pubitemid 32701405)
27. Mathews MB, Bernstein RM, Franza BR Jr, Garrels JI. Identity of the proliferating cell nuclear antigen and cyclin. Nature. 1984;309:374-6. (Pubitemid 14145846)
28. Bravo R, Frank R, Blundell PA, Macdonald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature. 1987;326:515-7. (Pubitemid 17055498)
29. Wong Kee Song LM, Wang KK, Zinsmeister AR. Mono-Laspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model. Cancer. 1998;82:421-7. (Pubitemid 28060262)
30. Kobayashi W, Liu Q, Matsumiya T, Nakagawa H, Yoshida H, Imaizumi T, et al. Photodynamic therapy upregulates expression of Mac-1 and generation of leukotriene B(4) by human polymorphonuclear leukocytes. Oral Oncol. 2004;40:506-10. (Pubitemid 38296836)
31. Moan J, Sommer S. Oxygen dependence of the photosensitizing effect of hematoporphyrin derivative in NHIK 3025 cells. Cancer Res. 1985;45:1608-10. (Pubitemid 15079112)
32. Henderson BW, Fingar VH. Relationship of tumor hypoxia and response to photodynamic treatment in an experimental mouse tumor. Cancer Res. 1987;47:3110-4. (Pubitemid 17082632)
33. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-5.
34. Eyssen-Hernandez R, Ladoux A, Frelin C. Differential regulation of cardiac heme oxygenase-1 and vascular endothelial growth factor mRNA expressions by hemin, heavy metals, heat shock and anoxia. FEBS Lett. 1996;382:229-33. (Pubitemid 26091437)
35. Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, Gomer CJ. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res. 2000;60:4066-9. (Pubitemid 30636586)
36. Jiang F, Zhang ZG, Katakowski M, Robin AM, Faber M, Zhang F, et al. Angiogenesis induced by photodynamic therapy in normal rat brains. Photochem Photobiol. 2004;79:494-8.
37. Ohtani K, Usuda J, Ichinose S, Ishizumi T, Hirata T, Inoue T, et al. High expression of GADD-45alpha and VEGF induced tumor recurrence via upregulation of IL-2 after photodynamic therapy using NPe6. Int J Oncol. 2008;32:397-403. (Pubitemid 351188306)
38. Benckert C, Jonas S, Cramer T, Von Marschall Z, Schäfer G, Peters M, et al. Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res. 2003;63:1083-92. (Pubitemid 36278442)
39. Mancino A, Mancino MG, Glaser S, Alpini G, Bolognese A, Izzo L, et al. Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor. Dig Liver Dis. 2008;41:156-63.
40. Hida Y, Morita T, Fujita M, Miyasaka Y, Horita S, Fujioka Y, et al. Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas. Anticancer Res. 1999;19:2257-60. (Pubitemid 29392531)
41. Möbius C, Demuth C, Aigner T, Wiedmann M, Wittekind C, Mössner J, et al. Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma. EJSO. 2007;33:1025-9. (Pubitemid 47408741)